Logo image of AYTU

AYTU BIOPHARMA INC (AYTU) Stock Fundamental Analysis

NASDAQ:AYTU - Nasdaq - US0547548588 - Common Stock - Currency: USD

2.05  +0.03 (+1.49%)

Fundamental Rating

3

Taking everything into account, AYTU scores 3 out of 10 in our fundamental rating. AYTU was compared to 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of AYTU have multiple concerns. AYTU scores decently on growth, while it is valued quite cheap. This could make an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year AYTU has reported negative net income.
In the past year AYTU had a positive cash flow from operations.
AYTU had negative earnings in each of the past 5 years.
In the past 5 years AYTU always reported negative operating cash flow.
AYTU Yearly Net Income VS EBIT VS OCF VS FCFAYTU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a decent Return On Assets value of -4.51%, AYTU is doing good in the industry, outperforming 76.26% of the companies in the same industry.
The Return On Equity of AYTU (-17.04%) is better than 72.73% of its industry peers.
Industry RankSector Rank
ROA -4.51%
ROE -17.04%
ROIC N/A
ROA(3y)-35%
ROA(5y)-27.17%
ROE(3y)-112.19%
ROE(5y)-78.65%
ROIC(3y)N/A
ROIC(5y)N/A
AYTU Yearly ROA, ROE, ROICAYTU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

AYTU has a better Gross Margin (67.43%) than 73.74% of its industry peers.
In the last couple of years the Gross Margin of AYTU has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for AYTU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.82%
GM growth 5Y-0.72%
AYTU Yearly Profit, Operating, Gross MarginsAYTU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

2

2. Health

2.1 Basic Checks

AYTU does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AYTU has more shares outstanding
The number of shares outstanding for AYTU has been increased compared to 5 years ago.
The debt/assets ratio for AYTU is higher compared to a year ago.
AYTU Yearly Shares OutstandingAYTU Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
AYTU Yearly Total Debt VS Total AssetsAYTU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -3.28, we must say that AYTU is in the distress zone and has some risk of bankruptcy.
AYTU's Altman-Z score of -3.28 is in line compared to the rest of the industry. AYTU outperforms 45.45% of its industry peers.
The Debt to FCF ratio of AYTU is 29.85, which is on the high side as it means it would take AYTU, 29.85 years of fcf income to pay off all of its debts.
AYTU has a better Debt to FCF ratio (29.85) than 76.26% of its industry peers.
A Debt/Equity ratio of 0.45 indicates that AYTU is not too dependend on debt financing.
AYTU has a Debt to Equity ratio (0.45) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF 29.85
Altman-Z -3.28
ROIC/WACCN/A
WACC18.04%
AYTU Yearly LT Debt VS Equity VS FCFAYTU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 0.98 indicates that AYTU may have some problems paying its short term obligations.
The Current ratio of AYTU (0.98) is worse than 82.32% of its industry peers.
AYTU has a Quick Ratio of 0.98. This is a bad value and indicates that AYTU is not financially healthy enough and could expect problems in meeting its short term obligations.
AYTU has a worse Quick ratio (0.81) than 82.83% of its industry peers.
Industry RankSector Rank
Current Ratio 0.98
Quick Ratio 0.81
AYTU Yearly Current Assets VS Current LiabilitesAYTU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 74.52% over the past year.
AYTU shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -24.58%.
The Revenue has been growing by 61.82% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)74.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%138.46%
Revenue 1Y (TTM)-24.58%
Revenue growth 3Y7.28%
Revenue growth 5Y61.82%
Sales Q2Q%2.54%

3.2 Future

AYTU is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.64% yearly.
AYTU is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.72% yearly.
EPS Next Y125.68%
EPS Next 2Y57.64%
EPS Next 3Y35.64%
EPS Next 5YN/A
Revenue Next Year-17.49%
Revenue Next 2Y-5.54%
Revenue Next 3Y-3.13%
Revenue Next 5Y9.72%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AYTU Yearly Revenue VS EstimatesAYTU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M
AYTU Yearly EPS VS EstimatesAYTU Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -50K -100K -150K

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

AYTU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 1.48, the valuation of AYTU can be described as very cheap.
Based on the Price/Forward Earnings ratio, AYTU is valued cheaply inside the industry as 98.99% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.94, AYTU is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 1.48
AYTU Price Earnings VS Forward Price EarningsAYTU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

97.98% of the companies in the same industry are more expensive than AYTU, based on the Enterprise Value to EBITDA ratio.
AYTU's Price/Free Cash Flow ratio is rather cheap when compared to the industry. AYTU is cheaper than 81.82% of the companies in the same industry.
Industry RankSector Rank
P/FCF 23.82
EV/EBITDA 1.66
AYTU Per share dataAYTU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

AYTU's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AYTU's earnings are expected to grow with 35.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y57.64%
EPS Next 3Y35.64%

More info and screens

0

5. Dividend

5.1 Amount

AYTU does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AYTU BIOPHARMA INC

NASDAQ:AYTU (5/22/2025, 12:20:52 PM)

2.05

+0.03 (+1.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)09-24 2025-09-24/amc
Inst Owners30.53%
Inst Owner Change-0.21%
Ins Owners2.35%
Ins Owner Change0.1%
Market Cap12.65M
Analysts82.86
Price Target8.16 (298.05%)
Short Float %2.26%
Short Ratio4.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)115.04%
Min EPS beat(2)8.96%
Max EPS beat(2)221.11%
EPS beat(4)3
Avg EPS beat(4)42.94%
Min EPS beat(4)-78.65%
Max EPS beat(4)221.11%
EPS beat(8)5
Avg EPS beat(8)-429.07%
EPS beat(12)7
Avg EPS beat(12)-308.62%
EPS beat(16)8
Avg EPS beat(16)-261.55%
Revenue beat(2)2
Avg Revenue beat(2)16.96%
Min Revenue beat(2)2.24%
Max Revenue beat(2)31.67%
Revenue beat(4)3
Avg Revenue beat(4)7.98%
Min Revenue beat(4)-3.7%
Max Revenue beat(4)31.67%
Revenue beat(8)5
Avg Revenue beat(8)0.23%
Revenue beat(12)7
Avg Revenue beat(12)1.02%
Revenue beat(16)8
Avg Revenue beat(16)-0.2%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)411.77%
EPS NQ rev (3m)178.95%
EPS NY rev (1m)0%
EPS NY rev (3m)20%
Revenue NQ rev (1m)49.71%
Revenue NQ rev (3m)49.71%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1.48
P/S 0.18
P/FCF 23.82
P/OCF 18.79
P/B 0.41
P/tB N/A
EV/EBITDA 1.66
EPS(TTM)-0.67
EYN/A
EPS(NY)1.39
Fwd EY67.67%
FCF(TTM)0.09
FCFY4.2%
OCF(TTM)0.11
OCFY5.32%
SpS11.14
BVpS4.99
TBVpS-3.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.51%
ROE -17.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.43%
FCFM 0.77%
ROA(3y)-35%
ROA(5y)-27.17%
ROE(3y)-112.19%
ROE(5y)-78.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.82%
GM growth 5Y-0.72%
F-Score5
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF 29.85
Debt/EBITDA 5.94
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion 28.57%
Profit Quality N/A
Current Ratio 0.98
Quick Ratio 0.81
Altman-Z -3.28
F-Score5
WACC18.04%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%138.46%
EPS Next Y125.68%
EPS Next 2Y57.64%
EPS Next 3Y35.64%
EPS Next 5YN/A
Revenue 1Y (TTM)-24.58%
Revenue growth 3Y7.28%
Revenue growth 5Y61.82%
Sales Q2Q%2.54%
Revenue Next Year-17.49%
Revenue Next 2Y-5.54%
Revenue Next 3Y-3.13%
Revenue Next 5Y9.72%
EBIT growth 1Y3.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year596.71%
EBIT Next 3Y126.9%
EBIT Next 5YN/A
FCF growth 1Y101.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y102.42%
OCF growth 3YN/A
OCF growth 5YN/A